Article Text

PDF
Original article
Effect of age and aortic valve anatomy on calcification and haemodynamic severity of aortic stenosis
  1. Mylène Shen1,
  2. Lionel Tastet1,
  3. Romain Capoulade1,
  4. Éric Larose1,
  5. Élisabeth Bédard1,
  6. Marie Arsenault1,
  7. Philippe Chetaille2,
  8. Jean G Dumesnil1,
  9. Patrick Mathieu1,
  10. Marie-Annick Clavel1,
  11. Philippe Pibarot1
  1. 1Institut Universitaire de Cardiologie et de Pneumologie de Québec/Quebec Heart & Lung Institute, Laval University, Quebec City, Quebec, Canada
  2. 2Department of Pediatrics, Centre Mère Enfants Soleil, Centre Hospitalier Universitaire de Québec, Laval University, Quebec City, Quebec, Canada
  1. Correspondence to Dr Philippe Pibarot, Institut Universitaire de Cardiologie et de Pneumologie de Québec, 2725 Chemin Sainte-Foy, Quebec City, Quebec, Canada G1V 4G5; philippe.pibarot{at}med.ulaval.ca

Abstract

Objective To evaluate the effect of age and aortic valve anatomy (tricuspid (TAV) vs bicuspid (BAV) aortic valve) on the relationship between the aortic valve calcification (AVC) and the haemodynamic parameters of aortic stenosis (AS) severity.

Methods Two hundred patients with AS and preserved left ventricular ejection fraction were prospectively recruited in the PROGRESSA (Metabolic Determinants of the Progression of Aortic Stenosis) study and underwent a comprehensive Doppler echocardiography and multidetector CT (MDCT). Mean transvalvular gradient (MG) measured by Doppler echocardiography was used to assess AS haemodynamic severity and AVC was evaluated by MDCT using the Agatston method and indexed to the left ventricular outflow tract area to obtain AVC density (AVCd). All analyses were adjusted for sex.

Results Thirty-nine patients had a BAV and 161 a TAV. Median age was 51 and 72 years for BAV and TAV patients, respectively. There was a modest correlation between MG and AVCd (ρ=0.51, p<0.0001) in the whole cohort. After dichotomisation for valve anatomy, there was a good correlation between AVCd and MG in the TAV group (ρ=0.61, p<0.0001) but weak correlation in the BAV group (ρ=0.32, p=0.046). In the TAV group, the strength of the AVCd–MG correlation was similar in younger (<72 years old; ρ=0.59, p<0.0001) versus older (≥72 years old; ρ=0.61, p<0.0001) patients. In the BAV group, there was no correlation between AVCd and MG in younger patients (<51 years old; ρ=0.12, p=0.65), whereas there was a good correlation in older patients (≥51 years old; ρ=0.55, p=0.009). AVCd (p=0.005) and age (p=0.02) were both independent determinants of MG in BAV patients while AVCd (p<0.0001) was the only independent determinant of MG in TAV patients.

Conclusions In patients with TAV as well as in older patients with BAV, AVCd appears to be the main factor significantly associated with the haemodynamic severity of AS and so it may be used to corroborate AS severity in case of uncertain or discordant findings at echocardiography. However, among younger patients with BAV, some may have a haemodynamically significant stenosis with minimal AVCd. The results of MDCT AVCd should thus be interpreted cautiously in this subset of patients.

Trial registration number NCT01679431; Pre-results.

Statistics from Altmetric.com

Footnotes

  • Contributors MS: study management, acquisition, analysis and interpretation of the data, preparation of the manuscript. LT: participation in the study management and acquisition of the data and critical revisions of the manuscript. RC: participation in the study management and acquisition of the data and critical revisions on the manuscript. EL: analysis of the CT exams. EB: analysis of the echocardiograms. MA: analysis of the echocardiograms. PC: critical revisions of the manuscript. JGD: critical revisions of the manuscript. PM: critical revisions of the manuscript. M-AC: assistance in the data analyses and critical revisions of the manuscript. PP: principal investigator of the PROGRESSA Study, supervision of the data acquisition, analyses and interpretation, critical revisions of the manuscript and validation of its final version.

  • Funding This work was supported by grants MOP-114997 and FDN-143225 from Canadian Institutes of Health Research (CIHR), Ottawa, Ontario, Canada and a grant from the Foundation of the Quebec Heart and Lung Institute. RC is supported by a postdoctoral fellowship grant from CIHR. EL, MA and PM are research scholars from the Fonds de Recherche Québec—Santé (FRQS), Montreal, Québec, Canada. PP holds the Canada Research Chair in Valvular Heart Diseases from CIHR, Ottawa, Ontario, Canada.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval Ethics Committee of the Quebec Heart and Lung Institute.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles